Oppenheimer analyst Andreas Argyrides raised the firm’s price target on Gossamer Bio (GOSS) to $12 from $9 and keeps an Outperform rating on the shares following quarterly results. Approaching the February 2026 PROSERA topline readout, the firm continues to see success given PROSERA’s baseline population and positive Phase 2 TORREY data increasing the likelihood of achieving statistically significant 6MWD. Additionally, the first clinical site from Phase 3 SERANATA/PH-ILD has been activated, with results expected in 2027.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GOSS: